Diasome Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Clevelandohiofounded In 2004The Company Specializes In Therapies For Metabolic Diseasesfocusing On Hepatocyte Targeting To Address Conditions Such As Diabetesobesityand Dyslipidemiadiasome Utilizes Its Proprietary Hepatocyte Directed Vesiclehdvtechnology To Enhance Insulin Deliveryaiming To Improve Glycemic Control And Reduce The Risk Of Hypoglycemia In Diabetes Patients The Company S Lead Product Is Hdv Insulin Therapydesigned To Direct Insulin To Liver Cellsmimicking The Liver S Natural Role In Glucose Regulationdiasome Is Advancing Several Candidates In Its Pipelineincluding An Insulin Lispro Biosimilar In Phase 2 Trials For Type 1 Diabetes And Hdv Formulations For Type 2 Diabetes In Early Phase 1 Trialsthe Company Has Conducted Multiple Human Trialsincluding The Isle 1 Phase 2B Study For Hdv Insulin In Type 1 Diabetesand Is Recognized For Its Innovative Approach To Insulin Therapy
